PulmonxLUNG
LUNG
About: Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
Employees: 279
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
21% more capital invested
Capital invested by funds: $242M [Q2] → $293M (+$50.3M) [Q3]
20% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 30
4% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 27
1% more funds holding
Funds holding: 111 [Q2] → 112 (+1) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
7.99% less ownership
Funds ownership: 98.44% [Q2] → 90.45% (-7.99%) [Q3]
100% less call options, than puts
Call options by funds: $10K | Put options by funds: $2.05M
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$7.50
22%
upside
Avg. target
$10.50
71%
upside
High target
$16
160%
upside
3 analyst ratings
1 positive
33%
2 neutral
67%
0 negative
0%
Wells Fargo Larry Biegelsen 51% 1-year accuracy 24 / 47 met price target | 30%upside $8 | Equal-Weight Maintained | 11 Dec 2024 |
Citigroup Joanne Wuensch 55% 1-year accuracy 26 / 47 met price target | 22%upside $7.50 | Neutral Downgraded | 11 Dec 2024 |
Stifel Rick Wise 62% 1-year accuracy 18 / 29 met price target | 160%upside $16 | Buy Maintained | 31 Oct 2024 |
Financial journalist opinion
Positive
Zacks Investment Research
4 weeks ago
Does Pulmonx (LUNG) Have the Potential to Rally 117.74% as Wall Street Analysts Expect?
The consensus price target hints at an 117.7% upside potential for Pulmonx (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
GlobeNewsWire
1 month ago
Pulmonx to Present at the Piper Sandler 36th Annual Healthcare Conference
REDWOOD CITY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference in New York on Wednesday, December 4, 2024, at 9:30 AM PT / 12:30 PM ET.
Neutral
Business Wire
1 month ago
Pulmonx Partners with American Lung Association to Launch New Educational Initiatives for COPD Patients and Providers
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, and the American Lung Association are continuing their ongoing collaboration with two new programs aimed at supporting patients with severe COPD and emphysema. Building on their successful partnership, the two organizations will launch new resources to educate patients and healthcare providers on innovative treatment options like the Ze.
Neutral
GlobeNewsWire
1 month ago
Pulmonx to Present at the Stifel 2024 Healthcare Conference
REDWOOD CITY, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Stifel 2024 Healthcare Conference in New York on Tuesday, November 19, 2024, at 6:10 AM PT / 9:10 AM ET.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Predict an 89.61% Upside in Pulmonx (LUNG): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 89.6% in Pulmonx (LUNG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Neutral
Seeking Alpha
1 month ago
Pulmonx Corporation (LUNG) Q3 2024 Earnings Call Transcript
Pulmonx Corporation (LUNG) Q3 2024 Earnings Call Transcript
Negative
Zacks Investment Research
1 month ago
Pulmonx Corporation (LUNG) Reports Q3 Loss, Misses Revenue Estimates
Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.39 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
Pulmonx to Report Third Quarter 2024 Financial Results on October 30, 2024
REDWOOD CITY, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2024 after the close of trading on Wednesday, October 30, 2024. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.
Neutral
GlobeNewsWire
3 months ago
Pulmonx Announces Presentation of Clinical Data from the AeriSeal® CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress 2024
CONVERT trial data demonstrate AeriSeal® System is safe and effective with 77.6% of patients converted from CV+ to CV-
Neutral
GlobeNewsWire
3 months ago
Pulmonx to Participate in the Lake Street 8th Annual Best Ideas Growth Conference
REDWOOD CITY, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in investor meetings at the Lake Street 8th Annual Best Ideas Growth Conference in New York on Thursday, September 14, 2024.
Charts implemented using Lightweight Charts™